TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01376167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine 300mg
Description: 300mg Chloroquine given to each subject on Day 3 of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine 300mg
Description: 300mg Chloroquine given to each subject on Day 3 of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine 300mg
Description: 300mg Chloroquine given to each subject on Day 3 of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine 300mg
Description: 300mg Chloroquine given to each subject on Day 3 of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 50mg
Description: single dose 50mg Tafenoquine given to subject on treatment arm 1 on Days 1 or 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 100mg
Description: single dose 100mg Tafenoquine given to subject on treatment arm 2 on Days 1 or 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 300mg
Description: single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 600mg
Description: single dose 600mg Tafenoquine given to subject on treatment arm 4 on Days 1 or 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine 15mg
Description: 15mg Primaquine given once daily to subject on treatment arm 5 on Days 2 to 15.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chloroquine 600mg (Part 2 )
Description: 600mg Chloroquine given to each subject on Day 1 and Day2 of the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine 600mg (Part 2 )
Description: 600mg Chloroquine given to each subject on Day 1 and Day2 of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine 600mg (Part 2 )
Description: 600mg Chloroquine given to each subject on Day 1 and Day2 of the trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chloroquine 300mg (Part 2 )
Description: 300mg Chloroquine given to each subject on Day 3 of the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine 300mg (Part 2 )
Description: 300mg Chloroquine given to each subject on Day 3 of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine 300mg (Part 2 )
Description: 300mg Chloroquine given to each subject on Day 3 of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 300mg (Part 2)
Description: single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine 15mg (Part2 )
Description: 15mg Primaquine given once daily to subject on treatment arm 3 on Days 2 to 15.
Study: NCT04163354

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 5% sodium fluoride varnish (NaF)
Description: In the NaF varnish groups, 0.25mL (one drop) of the varnish is placed in a plastic dappen dish. A disposable microbrush is used to apply the varnish onto the second primary molars included in the study and all other teeth. The child is instructed not to eat or drink after the application of varnish for at least half an hour.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant (GIS)
Description: Glass ionomer sealants (GIS) is applied using the finger pressure technique described in the WHO manual for atraumatic restorative treatment (ART) (Frencken et al.; 1997). The primary second molars are cleaned by applying GC cavity conditioner with micro-applicator for 10-15 seconds, then clean with wet cotton pellets for several times. The surface will be dried with cotton pellets. GIS (GC Fuji VII) is mixed in standardized proportion with an amalgamator, then applied to the occlusal surface and slightly overfilled. A gloved finger with petroleum jelly will be used to push and rub the materials into the pits and fissures, and removing the excess. GIS will be covered and protected by a layer of petroleum jelly (Vaseline ®).
Study: NCT03029832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOXR0916
Description: MOXR0916, 300 milligram (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab, 1200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
Study: NCT03682263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Service
Description: Receive Individual Placement and Support (IPS) model of employment services, behavioral health services, care management services, and Medication Management Support provided by a Nurse Care Coordinator (NCC).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Service
Description: Receive Individual Placement and Support (IPS) model of employment services, behavioral health services, and care management services.
Study: NCT05780268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3819253
Description: LY3819253 is a neutralizing immunoglobulin G (IgG)-1 monoclonal antibody (mAb) to the receptor binding domain (RBD) of the S protein of SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% sodium chloride solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Antiviral agent

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Antiviral agent
Study: NCT03986372

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platlet-rich plasma
Description: Multiple Platlet-rich plasma injection.
Study: NCT02712827

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progrip
Description: Self-fixating mesh

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Progrip
Description: Non self-fixating mesh with the use of glue
Study: NCT03986372

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platlet-rich plasma
Description: Multiple Platlet-rich plasma injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platlet-rich plasma
Description: Multiple Platlet-rich plasma injection.
Study: NCT04285840

Intervention type: OTHER
Group type: OTHER
Intervention: Venous ACT
Description: Matched/paired venous ACT samples will be drawn at the same time as arterial ACT samples to compare the results agreement between venous and arterial ACTs. Subjects undergoing atrial fibrillation ablations will continue to have Heparin dosed on the arterial ACT sample results only per the standard of care. Heparin will not be administered based on venous ACT levels obtained during this study.
Study: NCT01863654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg chewable tablets
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg chewable tablets
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg chewable tablets
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg chewable tablets
Description: Test product
Study: NCT01642732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Everolimus, lupron, bicalutamide, and radiation
Description: Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.~Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).~Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.~Lupron injections will begin on study day 15 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.~Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study.
Study: NCT01397734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: 0.15mg/kg/day Arsenic trioxide given IV on days 1-5 of the cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: 0.15mg/kg/day Arsenic trioxide given IV on days 1-5 of the cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: 0.15mg/kg/day Arsenic trioxide given IV on days 1-5 of the cycle.
Study: NCT03029832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab, 1200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
Study: NCT02467998

Intervention type: DEVICE
Intervention: NPWT
Description: SVAP polyurethane foam, RENASYS foam, RENASYS gauze, AMD gauze, VAC white sponge, VAC black sponge, applied with various NPWT devices, in addition to various dressings to protect wound edges
Study: NCT01166048

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: Patients will receive 120mg of Duloxetine for the duration of 2 weeks after a dosage titration of 2 weeks according to the following scheme: (p=placebo)~day: 1 2 3 4 5 6 7: p-30mg p-30mg p-30mg p-30 mg p-30mg p-30mg p-60mg~day: 8 9 10 11 12 13 14: p-60 mg p-60 mg p-60mg p-60mg p-60mg p-60mg 60-60mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 2 weeks of titration of duloxetine to 120mg, (1-0-1), 2 weeks of continuation on 120mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: 2 weeks of titration of duloxetine to 120mg, (1-0-1), 2 weeks of continuation on 120mg/day.
Study: NCT01382641

Intervention type: DEVICE
Group type: OTHER
Intervention: Hoya AF-1 IOL
Description: The patients will be assessed for three months

Intervention type: DEVICE
Group type: OTHER
Intervention: Revital vision
Description: The patients will be assessed for three months.
Study: NCT03471325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plaque disclosed with air flow
Description: air polishing with prior plaque disclosing
Study: NCT04395950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05221304
Description: PF-05221304 10 mg daily (two 5mg tablets daily in the morning for 6 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo two tablets daily in the morning for 6 weeks
Study: NCT00667173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-115
Description: Topical application for 12 weeks
Study: NCT02695797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVIG
Description: IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
Study: NCT05634772

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dormia basket
Description: Use of dormia basket in management of proximal stent migration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction biliary ballon
Description: Use of extraction biliary balloon in management of proximal stent migration
Study: NCT03471325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plaque disclosed with rubber cup
Description: rubber cup polishing with prior plaque disclosing
Study: NCT00667173

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical application for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical application for 12 weeks
Study: NCT03471325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non plaque disclosed air flow
Description: air polishing with no prior plaque disclosing

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non plaque disclosed rubber cup
Description: rubber cup polishing with no prior plaque disclosing
Study: NCT00842933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Cessation of corticosteroids 24 hours after cessation of vasopressors
Study: NCT00205907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLVR Hydrogel
Description: 10 mL BLVR Hydrogel
Study: NCT03505398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microperimetry
Description: define the retinal fixation point and the differential sensitivity threshold of the retina.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: microperimetry
Description: define the retinal fixation point and the differential sensitivity threshold of the retina.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microperimetry
Description: define the retinal fixation point and the differential sensitivity threshold of the retina.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: visual acuity
Description: using ETDRS scales

Intervention type: PROCEDURE
Group type: OTHER
Intervention: visual acuity
Description: using ETDRS scales

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: visual acuity
Description: using ETDRS scales
Study: NCT00842933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Administer daily for 7 days after diagnosis of acute adrenal insufficiency during septic shock
Study: NCT00323284

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent plus Cataract Surgery
Description: ab interno trabecular bypass stent surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery only
Description: Cataract surgery only
Study: NCT03606278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured debriefing assisted by video
Description: In the structured debriefing assisted by video, the process was based on the immediate review of the video, stopping and rewinding the recording as required. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured oral debriefing
Description: In the structured oral debriefing, the process was based by the mental search of their memories of what occurred. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.
Study: NCT01796886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pupillometry data
Study: NCT00115128

Intervention type: DRUG
Intervention: filgrastim
Description: Normal donors being treated with filgrastim for PBPC mobilization and collection
Study: NCT04000386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: zinc oxide nanoparticles coated socks
Description: zinc oxide nanoparticles coated socks were given to subjects for 2 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo socks
Description: placebo socks were given to subjects for 2 weeks
Study: NCT02115308

Intervention type: DRUG
Group type: OTHER
Intervention: Regadenoson
Description: Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.
Study: NCT03550781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone, cyclophosphamide
Description: Prednisone 0.5mg/(kg•d) and/or cyclophosphamide 2mg/kg
Study: NCT03292354

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contrast media administration
Description: All patients will receive contrast media with a concentration of 300 mg I/mL (Iopromide 300). The flowrate and volume will be calculated with help of the different formulas belonging to the three different arms.
Study: NCT03544580

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant with dentine chips
Description: Using dentin chips
Study: NCT03292354

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contrast media administration
Description: All patients will receive contrast media with a concentration of 300 mg I/mL (Iopromide 300). The flowrate and volume will be calculated with help of the different formulas belonging to the three different arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contrast media administration
Description: All patients will receive contrast media with a concentration of 300 mg I/mL (Iopromide 300). The flowrate and volume will be calculated with help of the different formulas belonging to the three different arms.
Study: NCT03544580

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional immediate implant
Description: using xenograft
Study: NCT01575613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination
Description: Focal screening and treatment in all households in malaria hotspots prior to the peak transmission season. Screening of a sentinel age group by rapid diagnostic tests; all parasitaemic individuals and household members of parasitaemic individuals will be treated.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus thuringiensis
Description: Treatment of all waterbodies within hotspots with Bti or Bs on weekly basis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Long lasting insecticide treated net (LLINs)
Description: Distribution of LLINs in all households in malaria hotspots; instruction about correct use.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Indoor Residual Spraying (IRS)
Description: 6-monthly IRS with deltamethrin in all households malaria hotspots.
Study: NCT04623957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ForgTin©
Description: The device is clamped behind the ear via two connected temple parts that pressed together around the connecting axis until an individual perfect wearing comfort is achieved. The pressure is adjusted so that the wearing of ForgTin© is barely noticed at all and may be changed at any time.~The aim is a slight pressure stimulation of clearly defined points behind the ear - thus wearing ForgTin© leads to a minimization of individual tinnitus noises.
Study: NCT03580330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Description: Individual in the intervention group receive a weekly educational health SMS for the intervention period of 1 year. SMS content covered different health themes providing health information on lifestyle, dietary habits, body weight, smoking, medications, importance of compliance, as well as symptoms and self-management of HTN and diabetes. Community individuals who were diagnosed and were receiving necessary care previous to the investigator's intervention were sent weekly informative health SMS, as well as customized SMSs reminders to follow up on their scheduled medical appointments (eg, to check their HbA1c levels and have their annual foot or eye exams).
Study: NCT02337387

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blosozumab
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blosozumab
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blosozumab
Description: Administered SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT00358449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mepolizumab
Description: Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg), 2.5 mg/kg , or 10 mg/kg by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mepolizumab
Description: Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg), 2.5 mg/kg , or 10 mg/kg by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.
Study: NCT03878485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRIdian Linac System from ViewRay
Description: * 0.35T MRI combined with a linear accelerator~* This device will be used for the Stereotactic MRI-guided Adaptive Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic MRI-guided Adaptive Radiotherapy
Description: -The MR-linac will be delivering the radiation
Study: NCT00667706

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic operation Sleeve Gastrectomy
Description: Laparoscopic Sleeve Gastrectomy will be performed employing a 5-6 trocar technique, and includes gastric resection starting 4-5 cm proximal to the pylorus, using a 38 fr. Bougie and endoscopic stapler with blue and green load.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic operation Roux-en-Y Gastric bypass
Description: Divided LRYGB will employ 5-7 trocars technique, and includes stapled jejunojejunostomy 30-50 cm distal to the Treitz ligament, gastric pouch of 20 cc., and antecolic, antegastric gastrojejunal anastomosis, either two layered hand-sawn, GIA, or EEA-25 -stapled, at surgeons preference. The length of the Roux limb will be 100 centimeters or 150 centimeters in patients with BMI of \<50, and \>50, respectively.
Study: NCT00358449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mepolizumab
Description: Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg), 2.5 mg/kg , or 10 mg/kg by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.